Discover
Cosentyx (secukinumab) / NovartispINPOINt: A Study of Secukinumab Treatment in Patients With Plaque Psoriasis and Coexisting Non-alcoholic Fatty Liver Disease (NAFLD) (clinicaltrials.gov) - Jan 23, 2020 - P3; N=90; Not yet recruiting; Sponsor: Novartis Pharmaceuticals
Stelara (ustekinumab) / J&JThe European Commission approves expanded use of Janssen’s Stelara (ustekinumab) for the treatment of paediatric patients with moderate to severe plaque psoriasis (Businesswire) - Jan 23, 2020 - "The Janssen Pharmaceutical Companies...today announced that the European Commission (EC) has approved the expanded use of STELARA® (ustekinumab) for the treatment of paediatric patients (ages 6–11) with moderate to severe plaque psoriasis. Ustekinumab...is now the first available biologic treatment in this patient population to selectively address the IL‑23/IL‑12 pathway...Safety data from CADMUS Jr were consistent with the known safety profiles reflected in respective current prescribing information labels and ustekinumab was generally well‑tolerated by paediatric patients with plaque psoriasis."
Skyrizi (risankizumab) / AbbVie, Boehringer IngelheimAbbVie presents new risankizumab results that show long-term sustained efficacy [Google Translation] (ConSalud.es) - Jan 21, 2020 - P3, N=782; LIMMItless (NCT03047395); Sponsor: AbbVie; "...AbbVie has presented new long-term results of safety and efficacy of SKYRIZI....These new data, presented in the framework of the V National Psoriasis Congress organized by the Psoriasis Group of the Spanish Academy of Dermatology and Venereology (AEDV), represent an advance in the treatment of adult patients with moderate to severe plaque psoriasis. The data presented within the LIMMItless study indicate that a statistically significant number of patients treated with risankizumab administered every 12 weeks continuously, achieved a complete or almost complete clearance after 136 weeks of treatment."
Otezla (apremilast) / AmgenApremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy (clinicaltrials.gov) - Jan 22, 2020 - P3; N=595; Active, not recruiting; Sponsor: Celgene; Recruiting --> Active, not recruiting
Skyrizi (risankizumab) / AbbVie, Boehringer IngelheimSkyrizi sales estimate: $275M in 2019; Skyrizi sales projection: $850M in 2020 and $3.4B in 2025 (Cowen & Co) - Jan 21, 2020 - A subscription to Thomson ONE is required to gain full access to report 68638151; Page no: 72; REPORT TITLE: "Pharmaceutical industry pulse"; AUTHOR: Scala, Stephen, et al; DATE: 01/13/2020
ABY-035 / AffibodyA double-blind study in subjects with active psoriatic arthritis to evaluate efficacy, tolerability, safety of two different dose levels of ABY-035 compared to placebo. (clinicaltrialsregister.eu) - Jan 21, 2020 - P2; N=129; Ongoing; Sponsor: Affibody AB
mirikizumab (LY3074828) / Eli LillyMirikizumab sales projection: $50M in 2021 and $250M in 2025 (Cowen & Co) - Jan 24, 2020 - A subscription to Thomson ONE is required to gain full access to report 68638151; Page no: 331; REPORT TITLE: "Pharmaceutical industry pulse"; AUTHOR: Scala, Stephen, et al; DATE: 01/13/2020
Cosentyx (secukinumab) / NovartisCosentyx sales estimate: $3.545B in 2019; Cosentyx sales projection: $5B peak, $3.805B in 2020 and $5.075B in 2025 (Cowen & Co) - Jan 22, 2020 - A subscription to Thomson ONE is required to gain full access to report 68638151; Page no: 589; REPORT TITLE: - “Pharmaceutical industry pulse”; AUTHOR: Scala, Stephen, et al; DATE: 01/13/2020
Taltz (ixekizumab) / Eli LillyTaltz sales estimate: $1.325B in 2019; Taltz sales projection: $1.73B in 2020 and $3.215B in 2025 (Cowen & Co) - Jan 24, 2020 - A subscription to Thomson ONE is required to gain full access to report 68638151; Page no: 321; REPORT TITLE: "Pharmaceutical industry pulse"; AUTHOR: Scala, Stephen, et al; DATE: 01/13/2020
BMS-986165 / BMSBMS-986165 sales projection: $50M in 2022 and $500M in 2025 (Cowen & Co) - Jan 23, 2020 - A subscription to Thomson ONE is required to gain full access to report 68638151; Page no: 260; REPORT TITLE: "Pharmaceutical industry pulse"; AUTHOR: Scala, Stephen, et al; DATE: 01/13/2020
